0

Gemotabine For Injection

Gemotabine For Injection
Gemotabine For Injection
Product Description
COMPOSITION:
Gemita (Gemcitabine for Injection USP) 200 mg
Each vial contains :
Gemcitabine Hydrochloride USP
Equivalent to Gemcitabine 200 mg
Mannitol IP 200 mg
Sodium acetate IP 12.5mg
Hydrochloric acid IP and/or Sodium hydroxide IP to adjust pH
Gemita (Gemcitabine for Injection USP) 1g
Each vial contains:
Gemcitabine Hydrochloride USP
Equivalent to Gemcitabine 1 g
Mannitol IP 1 g
Sodium acetate IP 62.5mg
Hydrochloric acid IP and/or Sodium hydroxide IP to adjust pH
Gemita (Gemcitabine for Injection USP) 1.4 g
Each vial contains:
Gemcitabine Hydrochloride USP
Equivalent to Gemcitabine 1.4 g
Mannitol IP 1.4 g
Sodium acetate IP 87.5mg
Hydrochloric acid IP and/or Sodium hydroxide IP to adjust pH

PRESENTATION :
 
Gemita (Gemcitabine for Injection USP) 200 mg is available as Sterile lyophilized powder for Injection in a 10 ml vial containing 200 mg of gemcitabine (base).
Gemita (Gemcitabine for Injection USP) 1 g is available as Sterile lyophilized powder for Injection in a 50 ml vial containing 1 g of gemcitabine (base).
Gemita (Gemcitabine for Injection USP) 1.4 g is available as Sterile lyophilized powder for Injection in 50 ml vial containing 1.4 g of gemcitabine (base).
   
INDICATIONS :
 
Ovarian Cancer :

Gemita in combination with carboplatin is indicated for the treatment of patients with advanced ovarian cancer that has relapsed at least 6 months after completion of platinum based therapy.
Breast Cancer :
  Gemita in combination with paclitaxel is indicated for the first-line treatment of patients with metastatic breast cancer after failure of prior anthracycline containing adjuvant chemotherapy, unless anthracyclines were clinically contraindicated.
Non-Small Cell Lung Cancer

Gemita is indicated in combination with cisplatin for the first-line treatment of patients with inoperable, locally advanced (Stage IIIA or IIIB), or metastatic (Stage IV) non-small cell lung cancer.
Pancreatic Cancer
  Gemita is indicated as first-line treatment for patients with locally advanced (nonresectable Stage II or Stage III) or metastatic (Stage IV) adenocarcinoma of the pancreas. Gemita is indicated for patients previously treated with 5-FU.
Contact Us

5, SUNDERVAN SOCIETY, NEAR NAVGUJARAT COLLEGE, ASHRAM ROAD, USMANPURA, Ahmedabad, Gujarat, 380013, India
Phone :+918068094469